Trial halted early: did this combo help control tough brain tumors?
NCT ID NCT07166367
Summary
This study tested whether adding the drug ASLAN001 to standard chemotherapy (capecitabine) could help control brain tumors in people with a specific type of breast cancer (HER2-positive). It was for patients whose brain tumors had started growing again after radiation treatment. The trial ended early after enrolling only 3 of a planned 29 participants, so its results are very limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Centre Singapore
Singapore, 169610, Singapore
Conditions
Explore the condition pages connected to this study.